Alnylam and Regeneron plan pivotal trial of brezosiran for Huntington's after encouraging early data

Alnylam and Regeneron are planning a pivotal trial of their RNA drug for Huntington's disease after encouraging early data, despite setbacks for rivals in the space.

Detected & updated continuously · Source: Nebula